PharmaAIv1.0.0

Pharmaceutical researchers use PharmaAI to screen large compound libraries for potential drug candidates, predicting toxicity and ADMET properties to prioritize molecules for synthesis and testing, reducing experimental costs and time.

Chemical manufacturers and regulatory bodies apply PharmaAI to evaluate the safety of new chemicals or industrial compounds, assessing risks like hERG toxicity and mutagenicity to ensure compliance with health and environmental standards.

University labs and research institutions utilize PharmaAI for virtual screening and toxicity prediction in drug design projects, enabling students and scientists to validate molecular hypotheses and optimize lead compounds efficiently.

Biotech startups leverage PharmaAI to accelerate drug development pipelines by performing batch analyses of candidate molecules, identifying safe and effective compounds for preclinical studies with minimal infrastructure investment.

Pharma companies employ PharmaAI to verify that drug candidates or existing formulations meet safety criteria like Lipinski's Rule of Five and ADMET profiles, ensuring product reliability and reducing late-stage failures.

Offer PharmaAI as a cloud-based service with tiered subscription plans for individual researchers, academic labs, and corporate teams, providing API access, batch processing, and regular model updates to generate recurring revenue.

Sell customized enterprise licenses to large pharmaceutical and chemical companies, including on-premise deployment, dedicated support, and integration with existing drug discovery platforms for high-value, long-term contracts.

Implement a pay-per-use model where users pay based on the number of predictions or batch analyses performed, appealing to small labs and occasional users who need flexible, cost-effective access without long-term commitments.